Long-Term Cardiovascular and Cerebrovascular Challenges Posed by COVID-19 in Patients With Familial Hypercholesterolemia.
作者信息
Vuorio Alpo, Raal Frederick, Ijäs Petra, Kaste Markku, Kovanen Petri T
机构信息
Mehiläinen, Airport Health Center, Vantaa, Finland.
Department of Forensic Medicine, University of Helsinki, Helsinki, Finland.
出版信息
Front Pharmacol. 2022 May 11;13:890141. doi: 10.3389/fphar.2022.890141. eCollection 2022.
Abstract
摘要
相似文献
1
Long-Term Cardiovascular and Cerebrovascular Challenges Posed by COVID-19 in Patients With Familial Hypercholesterolemia.新冠病毒给家族性高胆固醇血症患者带来的长期心血管和脑血管挑战
Front Pharmacol. 2022 May 11;13:890141. doi: 10.3389/fphar.2022.890141. eCollection 2022.
2
Prevention of Cardiovascular Burden in COVID-19 Patients Suffering from Familial Hypercholesterolemia: A Global Challenge.预防患有家族性高胆固醇血症的COVID-19患者的心血管负担：一项全球挑战。
Cardiol Ther. 2022 Mar;11(1):1-7. doi: 10.1007/s40119-021-00245-3. Epub 2021 Nov 17.
3
New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.新型 LDL 胆固醇降低治疗方法：药理学、临床试验及与急性冠脉综合征的相关性。
Clin Ther. 2013 Aug;35(8):1082-98. doi: 10.1016/j.clinthera.2013.06.019. Epub 2013 Aug 8.
4
Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.载脂蛋白 B 代谢途径抑制剂治疗杂合子型家族性高胆固醇血症或动脉粥样硬化性心血管疾病患者的成本效果分析。
JAMA. 2016 Aug 16;316(7):743-53. doi: 10.1001/jama.2016.11004.
5
Therapeutic efficacy of PCSK9 monoclonal antibodies in statin-nonresponsive patients with hypercholesterolemia and dyslipidemia: A systematic review and meta-analysis.前蛋白转化酶枯草溶菌素9单克隆抗体在他汀类药物无反应的高胆固醇血症和血脂异常患者中的治疗效果：一项系统评价和荟萃分析。
Int J Cardiol. 2016 Nov 1;222:119-129. doi: 10.1016/j.ijcard.2016.07.239. Epub 2016 Jul 30.
6
Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab.在 1578 例家族性高胆固醇血症患者中，PCSK9 抑制降低心血管事件：来自 Bocizumab 的 SPIRE 随机试验的结果。
J Clin Lipidol. 2018 Jul-Aug;12(4):958-965. doi: 10.1016/j.jacl.2018.03.088. Epub 2018 Apr 3.
7
Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale.阿利西尤单抗在非他汀类降脂治疗或最低强度他汀治疗未充分控制的高胆固醇血症患者中的疗效和安全性：ODYSSEY 日本研究设计与原理
Lipids Health Dis. 2017 Jun 17;16(1):121. doi: 10.1186/s12944-017-0513-7.
8
PCSK9 inhibitors: monoclonal antibodies for the treatment of hypercholesterolemia.前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂：用于治疗高胆固醇血症的单克隆抗体。
Drugs Today (Barc). 2016 Mar;52(3):183-92. doi: 10.1358/dot.2016.52.3.2440527.
9
High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry.杂合子家族性高胆固醇血症患者的复发性心血管事件负担高：法国家族性高胆固醇血症注册研究。
Atherosclerosis. 2018 Oct;277:334-340. doi: 10.1016/j.atherosclerosis.2018.08.010.
10
PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies.家族性高胆固醇血症中的 PCSK9 突变：从开创性发现到抗 PCSK9 疗法
Curr Atheroscler Rep. 2017 Oct 17;19(12):49. doi: 10.1007/s11883-017-0684-8.
引用本文的文献
1
Familial Hypercholesterolemia Patients with COVID-19-Effective Cholesterol-Lowering Therapy is Urgent both during and after Infection.家族性高胆固醇血症合并新型冠状病毒肺炎患者——感染期间及感染后均急需有效的降胆固醇治疗
Rev Cardiovasc Med. 2022 Dec 19;23(12):410. doi: 10.31083/j.rcm2312410. eCollection 2022 Dec.
2
Cerebrovascular Manifestations of SARS-CoV-2: A Comprehensive Review.新型冠状病毒肺炎的脑血管表现：综述
Curr Treat Options Neurol. 2023;25(4):71-92. doi: 10.1007/s11940-023-00747-6. Epub 2023 Mar 4.
本文引用的文献
1
Long-term cardiovascular outcomes of COVID-19.COVID-19 长期心血管后果。
Nat Med. 2022 Mar;28(3):583-590. doi: 10.1038/s41591-022-01689-3. Epub 2022 Feb 7.
2
Subclinical Myocardial Dysfunction in Patients with Persistent Dyspnea One Year after COVID-19.新冠病毒感染后一年仍持续存在呼吸困难患者的亚临床心肌功能障碍
Diagnostics (Basel). 2021 Dec 28;12(1):57. doi: 10.3390/diagnostics12010057.
3
Lipoprotein(a), venous thromboembolism and COVID-19: A pilot study.脂蛋白(a)、静脉血栓栓塞和 COVID-19：一项初步研究。
Atherosclerosis. 2022 Jan;341:43-49. doi: 10.1016/j.atherosclerosis.2021.12.008. Epub 2021 Dec 21.
4
A clinical case definition of post-COVID-19 condition by a Delphi consensus.德尔菲共识对新冠后状况的临床病例定义。
Lancet Infect Dis. 2022 Apr;22(4):e102-e107. doi: 10.1016/S1473-3099(21)00703-9. Epub 2021 Dec 21.
5
Prevention of Cardiovascular Burden in COVID-19 Patients Suffering from Familial Hypercholesterolemia: A Global Challenge.预防患有家族性高胆固醇血症的COVID-19患者的心血管负担：一项全球挑战。
Cardiol Ther. 2022 Mar;11(1):1-7. doi: 10.1007/s40119-021-00245-3. Epub 2021 Nov 17.
6
Hypercholesterolemia and COVID-19: Statins for Lowering the Risk of Venous Thromboembolism.高胆固醇血症与2019冠状病毒病：他汀类药物用于降低静脉血栓栓塞风险
Front Cardiovasc Med. 2021 Oct 13;8:711923. doi: 10.3389/fcvm.2021.711923. eCollection 2021.
7
Long COVID: long-term effects?长期新冠：长期影响？
Eur Heart J Suppl. 2021 Oct 8;23(Suppl E):E1-E5. doi: 10.1093/eurheartj/suab080. eCollection 2021 Oct.
8
Familial hypercholesterolemia and COVID-19: A menacing but treatable vasculopathic condition.家族性高胆固醇血症与2019冠状病毒病：一种危险但可治疗的血管病变状况。
Atheroscler Plus. 2021 Sep;43:3-6. doi: 10.1016/j.athplu.2021.08.001. Epub 2021 Aug 8.
9
COVID-19 associated risks of myocardial infarction in persons with familial hypercholesterolemia with or without ASCVD.伴有或不伴有动脉粥样硬化性心血管疾病（ASCVD）的家族性高胆固醇血症患者中与COVID-19相关的心肌梗死风险
Am J Prev Cardiol. 2021 May 25;7:100197. doi: 10.1016/j.ajpc.2021.100197. eCollection 2021 Sep.
10
Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin.长期 COVID/COVID-19 后急性后遗症（PASC）中持续存在的凝血蛋白病理学伴随着抗纤溶酶水平的升高。
Cardiovasc Diabetol. 2021 Aug 23;20(1):172. doi: 10.1186/s12933-021-01359-7.
Zotero 插件